NEW YORK--(BUSINESS WIRE)--Jun 14, 2018--Levi & Korsinsky announces it has commenced an investigation of Flex Pharma, Inc. (“Flex Pharma” or “the Company”) (NASDAQGM: FLKS) concerning possible violations of federal securities laws.

On June 13, 2018, Flex Pharma announced it would cease its “ongoing Phase 2 clinical trial investigations of FLX-787 in amyotrphic lateral sclerosis and Charcot-Marie-Tooth due to oral tolerability concerns observed in a subset of patients…” The Company also announced a restructuring plan that includes reducing its workforce by approximately 60 percent. Following this news, shares of Flex Pharma fell from a close of $4.18 per share on June 12, 2018, to a close of $1.04 per share on June 13, 2018. To obtain additional information, go to:

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180614006122/en/

CONTACT: Levi & Korsinsky, LLP

Eduard Korsinsky, Esq.

Tel: 212-363-7500

Toll Free: 877-363-5972

Fax: 212-363-7171

www.zlk.com

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK

INDUSTRY KEYWORD: PROFESSIONAL SERVICES LEGAL

SOURCE: Levi & Korsinsky, LLP

Copyright Business Wire 2018.

PUB: 06/14/2018 03:14 PM/DISC: 06/14/2018 03:14 PM

http://www.businesswire.com/news/home/20180614006122/en